Skip to Content

Genitope Corporation to Host Conference Call to Discuss Initial Results of Phase 3 Clinical Trial

FREMONT, Calif.--(BUSINESS WIRE)--Dec 20, 2007 - Genitope Corporation (NASDAQ: GTOP) announced that it will hold a conference call today at 2 p.m. PST/5 p.m. EST to discuss the initial results of its pivotal Phase 3 clinical trial examining MyVax(R) personalized immunotherapy in previously untreated follicular B-cell non-Hodgkin's lymphoma. The company intends to issue a press release after 4:00 p.m. EST today announcing the initial results of its Phase 3 clinical trial.

Conference Call Information:

Domestic callers: 866.314.4865

International callers: 617.213.8050

Passcode: 95561171

Webcast information:

The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (

A replay of the conference call will be available beginning at 4:00 p.m. PST on December 20, 2007 through 11:59 p.m. PST on December 27, 2007. Access numbers for this replay are: 1-888-286-8010 (U.S./Canada) and 1-617-801-6888 (international). The access code for the replay is 94221341. Additionally, the webcast will be available for 30 days.

About Genitope Corporation

Genitope Corporation (Fremont, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax(R) personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells. For more information on the company, please log on to


Genitope Corporation
Media Contact:
Lorie Fiber, 310-383-6583
Investor Contact:
John Vuko, 510-284-3000
Chief Financial Officer

Posted: December 2007